Literature DB >> 28877085

Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset.

Antje Timmer1, Renee Stark, Jenny Peplies, Martin Classen, Martin W Laass, Sibylle Koletzko.   

Abstract

OBJECTIVE: There are inconsistent reports on age-related differences in inflammatory bowel disease (IBD). On the basis of patient information, we describe the clinical presentation and therapy in relation to age at diagnosis in longstanding pediatric IBD. PATIENTS AND METHODS: Two surveys were conducted in children and young adults (age: 10-25 years) by pretested postal questionnaires. The main analyses are descriptive, showing proportions and distributions per grouped age of diagnosis. Exploratory logistic regression was used to identify sociodemographic and disease-related factors associated with prognosis. Recent disease course, use of biological therapy, and resecting surgery were chosen as indicators of disease severity. Patients with a diagnosis in infancy (<2 years of age) are presented as a case series.
RESULTS: Information of 1280 cases was available [804 Crohn's disease (CD), 382 ulcerative colitis (UC), 94 IBD not specified] (response: 44.6 and 49.6%). Stable remission during the preceding year was reported by 675 (56.7%) patients; 825 (60.9%) patients reported feeling currenty well. Anti-tumor necrosis factor therapy was reported by 33% of CD patients and 9.3% of UC patients, immunomodulation in 82.1 and 63.2%, and corticosteroids by 78.4 and 76.1%, respectively (ever use). Age at diagnosis was not associated with indicators of severe disease. Diagnosis in infancy was reported by 37 patients.
CONCLUSION: Our data do not support age at diagnosis-related differences in prognosis in pediatric-onset IBD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28877085     DOI: 10.1097/MEG.0000000000000956

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Modeling determinants of satisfaction with health care in youth with inflammatory bowel disease: a cross-sectional survey.

Authors:  Antje Timmer; Dominik de Sordi; Elise Menke; Jenny Peplies; Martin Claßen; Sibylle Koletzko; Fabian Otto-Sobotka
Journal:  Clin Epidemiol       Date:  2018-09-25       Impact factor: 4.790

2.  School-related experience and performance with inflammatory bowel disease: results from a cross-sectional survey in 675 children and their parents.

Authors:  Magdalena Freckmann; Alexander Seipp; Martin W Laass; Sibylle Koletzko; Martin Claßen; Antje Ballauff; Jenny Peplies; Antje Timmer
Journal:  BMJ Open Gastroenterol       Date:  2018-11-24

3.  Modeling determinants of satisfaction with health care in youth with inflammatory bowel disease part 2: semiparametric distributional regression.

Authors:  Fabian Otto-Sobotka; Jenny Peplies; Antje Timmer
Journal:  Clin Epidemiol       Date:  2019-05-16       Impact factor: 4.790

4.  Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry.

Authors:  Ivana Kern; Olaf Schoffer; Wieland Kiess; Jobst Henker; Martin W Laaß; Ulf Winkler; Jürgen Quietzsch; Olaf Wenzel; Marlen Zurek; Katrin Büttner; Peter Fischer; Jan de Laffolie; Ulf Manuwald; Thoralf Stange; Ronny Zenker; Jens Weidner; Klaus-Peter Zimmer; Hildebrand Kunath; Joachim Kugler; Thomas Richter; Ulrike Rothe
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

5.  Inflammatory Bowel Disease: A Personalized Approach.

Authors:  Anastasia Konidari; David Dickens; Munir Pirmohamed
Journal:  Front Pediatr       Date:  2021-02-11       Impact factor: 3.418

6.  Current and projected incidence trends of pediatric-onset inflammatory bowel disease in Germany based on the Saxon Pediatric IBD Registry 2000-2014 -a 15-year evaluation of trends.

Authors:  Ivana Kern; Olaf Schoffer; Thomas Richter; Wieland Kiess; Gunter Flemming; Ulf Winkler; Jürgen Quietzsch; Olaf Wenzel; Marlen Zurek; Ulf Manuwald; Janice Hegewald; Shi Li; Jens Weidner; Jan de Laffolie; Klaus-Peter Zimmer; Joachim Kugler; Martin W Laass; Ulrike Rothe
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.